insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

DRMA · Dermata Therapeutics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · DRMA

1Y3YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$383.7K-$504.4K$617.8K$1.28M-$2.40M$2.01M$1.60M-
SG&A$1.06M-$1.26M$1.15M$1.06M-$824.3K$874.6K$1.60M-
Total Operating Expenses$1.93M-$1.76M$1.77M$2.34M-$3.23M$2.88M$3.20M-
D&A----------
Operating Income($1.93M)-($1.76M)($1.77M)($2.34M)-($3.23M)($2.88M)($3.20M)-
Interest Expense----------
Income Tax----------
Net Income($1.85M)-($1.69M)($1.70M)($2.30M)-($3.17M)($2.83M)($3.13M)-
EPS - Basic($0.48)-($1.65)($1.66)($70.60)-----
EPS - Diluted($0.48)-($20.41)($1.66)($70.60)-----

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$6.95M$7.52M$4.66M$6.48M$3.16M$3.16M$6.14M$4.95M$4.73M$7.44M
Accounts Receivable----------
Inventory$93.1K---------
Accounts Payable$318.3K$460.8K$453.4K$413.7K$1.40M$808.0K$863.6K$1.33M$822.5K$866.0K
Current Assets----------
Total Assets$7.47M$7.86M$5.07M$6.64M$10.01M$3.53M$6.69M$5.24M$5.18M$7.98M
Current Liabilities----------
Long-term Debt----------
Total Liabilities$1.05M$1.64M$1.11M$1.03M$2.70M$1.97M$1.95M$1.92M$1.37M$1.62M
Stockholders' Equity$6.41M$6.22M$3.96M$5.61M$7.30M$1.56M$4.74M$3.32M$3.81M$6.36M
Retained Earnings($75.08M)($73.23M)($71.37M)($69.68M)($67.98M)($65.68M)($62.52M)($59.35M)($56.52M)($53.39M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($2.48M)---($1.93M)---($2.70M)-
Investing Cash Flow----------
Financing Cash Flow$1.90M---$8.49M---$0-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-24.7%--33.4%-25.6%-23.0%--47.5%-54.0%-60.5%-
Return on equity-28.8%--42.7%-30.3%-31.6%--66.9%-85.3%-82.3%-
Return on invested capital----------
Liquidity
Current ratio----------
Quick ratio----------
Cash ratio----------
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.161.261.281.181.372.261.411.581.361.26
Liabilities / Assets0.140.210.220.150.270.560.290.370.260.20
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B0.7x-0.2x1.1x0.7x-----
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)17.7%-45.4%38.5%27.0%--78.0%-66.5%-40.7%-
Net income growth (YoY)19.8%-46.7%39.9%26.5%--84.6%-66.3%-39.9%-
EPS growth (YoY)99.3%---------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-12.2%298.7%-16.5%69.2%91.7%-75.4%-26.0%-58.7%-52.9%5.5%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Dermata Therapeutics against the 5 most active filers in the same SIC group.